Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Launched by ASTRAZENECA · Jun 2, 2008
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • FEV1 between 30 and 80% of predicted normal value post-bronchodilator (GOLD stages 2 and 3)
- • Clinical diagnosis of COPD
- Exclusion Criteria:
- • Other clinically relevant disease or disorders
- • Exacerbation of COPD within 30 days
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pleven, , Bulgaria
Russe, , Bulgaria
Sofia, , Bulgaria
Varna, , Bulgaria
Lublin, , Poland
Lund, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Arhus C, , Denmark
Krakow, , Poland
Hellerup, , Denmark
Poprad, , Slovakia
Zilina, , Slovakia
Hvidovre, , Denmark
Vaerlose, , Denmark
Bojnice, , Slovakia
Ostrow Wielkopolski, , Poland
Rzeszow, , Poland
Liptovsky Hradok, , Slovakia
Przemysl, , Poland
Spisska Nova Ves, , Slovakia
Patients applied
Trial Officials
Jörgen Vestbo
Principal Investigator
Professor in Respiratory Medicine, Hvidovre, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials